Lotus Pharmaceutical Co., Ltd. (1795.TW)
Taiwan · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$174.00 (+0.29%) as of
Key statistics
- Market cap
- 46.36B
- P/E (TTM)
- 12.17
- Forward P/E
- 7.31
- EPS (TTM)
- 14.30
- Dividend yield
- 1.49%
- 52-week range
- 168.31 – 364.76
- Beta
- 0.66
- Revenue (TTM)
- 28.49B
- Profit margin
- 13.22%
- Analyst target
- NT$292.32
- Volume
- 149.03k
About Lotus Pharmaceutical Co., Ltd.
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. In addition, it offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.